文献速递免疫规划卫生政策与健康促进

评估接种COVID-19疫苗后非COVID-19死亡风险的安全性研究

A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination.
PubMed 文献 · Vaccine · 2022-12-20

该回顾性队列研究纳入2020年12月14日至2021年8月31日七家疫苗安全数据链站点的成员,针对美国使用的三种COVID-19疫苗分别分析接种后非COVID-19死亡风险,并用倾向评分调整混杂因素。结果显示各疫苗各剂次调整后风险比均低于1,未发现非COVID-19死亡风险升高,但作者指出调整后仍存在残余混杂偏倚。

要点

  • 接种BNT162b2第1剂后非COVID-19死亡的aHR为0.46(95%CI 0.44-0.49),第2剂后为0.48(95%CI 0.46-0.50)。
  • 接种mRNA-1273第1剂后aHR为0.41(95%CI 0.39-0.44),第2剂后为0.38(95%CI 0.37-0.40)。
  • 接种Ad26.COV2.S后aHR为0.55(95%CI 0.51-0.59),三种疫苗均未发现非COVID-19死亡风险升高。

核心结论

  • 在调整个体层面和社区层面多种危险因素后,美国使用的三种COVID-19疫苗接种者中未发现非COVID-19死亡风险升高;作者指出调整后仍存在残余混杂偏倚。

研究设计与样本

  • 回顾性队列研究,成员来自七家疫苗安全数据链站点,时间为2020年12月14日至2021年8月31日。
  • 针对美国使用的三种COVID-19疫苗分别进行三项独立分析,采用计数过程模型进行生存分析,以日历时间为基础时间尺度。
  • 采用倾向评分方法调整接种组与对照组之间混杂因素的潜在不平衡。

主要发现

  • 在各疫苗类型及年龄、性别、种族/族裔各组中,COVID-19疫苗接种者的粗非COVID-19死亡率均低于对照组。
  • BNT162b2第1剂后非COVID-19死亡aHR为0.46(95%CI 0.44-0.49),第2剂后为0.48(95%CI 0.46-0.50)。
  • mRNA-1273第1剂后aHR为0.41(95%CI 0.39-0.44),第2剂后为0.38(95%CI 0.37-0.40)。
  • Ad26.COV2.S接种后aHR为0.55(95%CI 0.51-0.59)。

关键数值与推荐

  • BNT162b2:第1剂后aHR 0.46(95%CI 0.44-0.49),第2剂后aHR 0.48(95%CI 0.46-0.50)。
  • mRNA-1273:第1剂后aHR 0.41(95%CI 0.39-0.44),第2剂后aHR 0.38(95%CI 0.37-0.40)。
  • Ad26.COV2.S:接种后aHR 0.55(95%CI 0.51-0.59)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出,在调整多种个体层面和社区层面危险因素后,仍存在残余混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety of COVID-19 vaccines plays an important role in addressing vaccine hesitancy. We conducted a large cohort study to evaluate the risk of non-COVID-19 mortality after COVID-19 vaccination while adjusting for confounders including individual-level demographics, clinical risk factors, health care utilization, and community-level socioeconomic risk factors. METHODS: The retrospective cohort study consisted of members from seven Vaccine Safety Datalink sites from December 14, 2020 through August 31, 2021. We conducted three separate analyses for each of the three COVID-19 vaccines used in the US. Crude non-COVID-19 mortality rates were reported by vaccine type, age, sex, and race/ethnicity. The counting process model for survival analyses was used to analyze non-COVID-19 mortality where a new observation period began when the vaccination status changed upon receipt of the first dose and the second dose. We used calendar time as the basic time scale in survival analyses to implicitly adjust for season and other temporal trend factors. A propensity score approach was used to adjust for the potential imbalance in confounders between the vaccinated and comparison groups. RESULTS: For each vaccine type and across age, sex, and race/ethnicity groups, crude non-COVID-19 mortality rates among COVID-19 vaccinees were lower than those among comparators. After adjusting for confounders with the propensity score approach, the adjusted hazard ratios (aHRs) were 0.46 (95% confidence interval [CI], 0.44-0.49) after dose 1 and 0.48 (95% CI, 0.46-0.50) after dose 2 of the BNT162b2 vaccine, 0.41 (95% CI, 0.39-0.44) after dose 1 and 0.38 (95% CI, 0.37-0.40) after dose 2 of the mRNA-1273 vaccine, and 0.55 (95% CI, 0.51-0.59) after receipt of Ad26.COV2.S. CONCLUSION: While residual confounding bias remained after adjusting for several individual-level and community-level risk factors, no increased risk was found for non-COVID-19 mortality among recipients of three COVID-19 vaccines used in the US.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Xu S, Huang R, Sy LS, et al. A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. Vaccine. 2022. PMID: 36564276. doi:10.1016/j.vaccine.2022.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。